Open AccessSingle‐Dose and Multiple‐Dose Pharmacokinetics of Vaniprevir in Healthy Men
Author(s) -
Caro L,
Hoon J,
Depré M,
Cilissen C,
Miller J,
Gao W,
Panebianco D,
Guo Z,
Troemel SL,
Anderson MS,
Uemura N,
Butterton J,
Wagner J,
Wright DH
Publication year - 2017
Publication title -
clinical and translational science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.303
H-Index - 44
eISSN - 1752-8062
pISSN - 1752-8054
DOI - 10.1111/cts.12482
Subject(s) - pharmacokinetics , tolerability , medicine , placebo , adverse effect , pharmacology , area under the curve , hepatitis c , gastroenterology , pathology , alternative medicine
Vaniprevir is an inhibitor of the hepatitis C virus (HCV) NS3/4A protease. The aim of these double‐blind, placebo‐controlled phase I studies was to evaluate the safety and pharmacokinetics of vaniprevir in healthy male volunteers. The primary objective for both studies was the safety and tolerability of vaniprevir. Single‐dose and steady‐state pharmacokinetics were also assessed. In both studies, there was no apparent relationship between the frequency or intensity of adverse events and vaniprevir dose. At single doses >20 mg, the plasma area under the curve (AUC) 0–∞ and maximum concentration (C max ) increased in a greater‐than‐dose‐proportional manner. The geometric mean ratios (GMRs; fed/fasted) were 1.22 and 0.79 for AUC 0–∞ and C max , respectively. Following multiple doses, GMR accumulations for AUC 0–12h and C max (day 14/day 1) ranged from 1.53 to 1.90 and from 1.41 to 1.92, respectively. These data support the use of vaniprevir with peginterferon and ribavirin in patients with HCV infection.